Chronic urticaria
View article
Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta‐analysis Open
Background and objectives Urticaria is a frequent skin condition, but reliable prevalence estimates from population studies particularly of the chronic form are scarce. The objective of this study was to systematically evaluate and summari…
View article
European S2k Guideline on Chronic Pruritus Open
Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus at least once in the lifetime with a 12-month incidence of 7%. In patient populati…
View article
<span>BSACI</span> guideline for the management of chronic urticaria and angioedema Open
Summary This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology ( BSACI ). The guideline is based on…
View article
The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from <span>ASSURE</span>‐<span>CSU</span> Open
Background Chronic spontaneous urticaria ( CSU ) can be debilitating, difficult to treat, and frustrating for patients and physicians. Real‐world evidence for the burden of CSU is limited. The objective of this study was to document diseas…
View article
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria Open
The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -antihistamine treatment. Omalizumab…
View article
Ligelizumab for Chronic Spontaneous Urticaria Open
A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT024773…
View article
Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study Open
Background Autoimmune chronic spontaneous urticaria (aiCSU) is an important subtype of chronic spontaneous urticaria (CSU) in which functional IgG autoantibodies to IgE or its high‐affinity receptor (FcεRI) induces mast cell degranulation …
View article
Prevalence and Risk Factors of Urticaria With a Focus on Chronic Urticaria in Children Open
A total of 1.8% of children were found to have chronic urticaria. Living in a new residence and belonging to a family with a high income increased the risk of chronic continuous urticaria.
View article
Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria Open
Benefits and safety of omalizumab in the real-world treatment of CIU meet or exceed results gleaned from clinical trials. These real-world data on omalizumab in CIU may help inform both clinical treatment expectations and policy decision m…
View article
Predictors of treatment response in chronic spontaneous urticaria Open
The current therapeutic algorithm for chronic spontaneous urticaria (CSU), endorsed by the international guideline, entails treatment escalation from second‐generation H 1 ‐antihistamines (sgAHs) to omalizumab and cyclosporine until comple…
View article
Total IgE as a Marker for Chronic Spontaneous Urticaria Open
The results of our review suggest that total IgE is a valuable marker for CSU, and we recommend its assessment in the routine diagnostic workup of CSU patients.
View article
Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy Open
Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study invest…
View article
Clinical Features of Chronic Spontaneous Urticaria that Predict Disease Prognosis and Refractoriness to Standard Treatment Open
Chronic spontaneous urticaria (CSU) is characterized by heterogeneous activity, evolution, associated comorbidities and response to treatment. The aim of this study was to identify prognostic factors in patients with CSU that predict disea…
View article
Management of chronic urticaria in children: a clinical guideline Open
The aim of this guidance is to provide recommendations to clinicians and other interested parties on chronic urticaria in children. The Italian Society for Pediatrics (SIP), the Italian Society for Allergy and Immunology (SIAIP), the Itali…
View article
Impact of chronic urticaria on quality of life and work in Japan: Results of a real‐world study Open
Little attention has been given to the burden of chronic urticaria ( CU ) in Japan compared with other skin diseases, such as atopic dermatitis ( AD ) and psoriasis. The primary objective of the RELEASE study was to evaluate the real‐life …
View article
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines Open
This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CSU‐related outcomes were considered. The r…
View article
Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria Open
Purpose: Patients with chronic spontaneous urticaria (CSU) have an increased risk for comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we evaluated clinical and laboratory features of CSU associated wi…
View article
The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria Open
Introduction The COVID‐19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim To understand how CU patients are affected by the COVID…
View article
Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria Open
Chronic spontaneous urticaria (CSU) is considered in a subset of patients to be an autoimmune disorder. Interleukin(IL)-17, IL-31, and IL-33 are involved in some immune response. The aim of this study was to quantify plasma IL-17, IL-31, a…
View article
Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria Open
Categorical UAS7TD disease states can discriminate between measures when considering the impact of urticaria activity. Using five categorical disease states could simplify clinical assessment and monitoring of treatment efficacy.
View article
Impact of chronic urticaria on the quality of life of patients followed up at a university hospital Open
Chronic urticaria compromises patients' quality of life, mainly those with more severe disease or who are diagnosed with chronic autoimmune urticaria.
View article
A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria Open
Both spontaneous and inducible forms of chronic urticaria pose a significant economic burden and have an adverse effect on patients' quality of life. The international guidelines and US practice parameters for the diagnosis and management …
View article
Antihistamine‐resistant chronic spontaneous urticaria: 1‐year data from the AWARE study Open
Summary Background Previous reports indicate that patients with chronic spontaneous urticaria ( CSU ) are undertreated and that physicians show poor adherence to guideline recommendations. Awareness of CSU has improved in recent years, but…
View article
Management and treatment of chronic urticaria (<span>CU</span>) Open
Developments increasing our understanding of chronic urticaria have resulted in the simplification and improvement of available treatments. Currently, many treatments target mast cell mediators, but we can now disrupt mast cell activation …
View article
Sleep Disturbance in Patients with Urticaria and Atopic Dermatitis: An Underestimated Burden Open
This study examined the relationship between insomnia and the frequent itching skin diseases, atopic dermatitis and chronic urticaria. Patients with chronic inflammatory dermatological diseases with pruritus were evaluated for insomnia (In…
View article
Chronic urticaria and the pathogenic role of mast cells Open
The signs and symptoms of chronic urticaria (CU) are caused by the activation and degranulation of skin mast cells (MCs). Recent studies have added to our understanding of how and why skin MCs are involved and different in CU. Also, novel …
View article
Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐<span>ACT</span> study data Open
Background The X‐ ACT study aimed to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria ( CSU ) patients with angioedema refractory to high doses of H 1 ‐antihistamines. Methods In X‐ ACT ,…
View article
Guideline of Chronic Urticaria Beyond Open
Urticaria is a relatively common condition that if chronic can persist for weeks, months or years and affect quality of life significantly. The etiology is often difficult to determine, especially as it becomes chronic. Many cases of chron…
View article
Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion Open
Chronic spontaneous urticaria (CSU) is characterized by the sudden, continuous or intermittent appearance of pruritic wheals (hives), angioedema, or both for six weeks or more, with no known specific trigger. The international EAACI/GA2LEN…
View article
Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies Open
Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urtica…